

# trastuzumab deruxtecan powder for concentrate for solution for infusion (Enhertu<sup>®</sup>)

Daiichi Sankyo UK Limited

05 July 2024

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation **trastuzumab deruxtecan (Enhertu<sup>®</sup>)** is not recommended for use within NHSScotland.

**Indication under review:** as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

## Advice context:

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

Chair  
Scottish Medicines Consortium